Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Resource utilisation and quality of life following initiation of insulin detemir in patients with type 2 diabetes mellitus.

Liebl A, Andersen H, Svendsen AL, Vora J, Yale JF; SOLVE Study Group.

Int J Clin Pract. 2013 Aug;67(8):740-9. doi: 10.1111/ijcp.12133.

PMID:
23869677
2.
3.

Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.

Vora J, Caputo S, Damci T, Orozco-Beltran D, Pan C, Svendsen AL, Sølje KS, Khunti K; SOLVE study group.

J Clin Pharm Ther. 2014 Apr;39(2):136-43. doi: 10.1111/jcpt.12116. Epub 2013 Dec 13.

PMID:
24329524
4.

Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.

Khunti K, Damci T, Meneghini L, Pan CY, Yale JF; SOLVE Study Group.

Diabetes Obes Metab. 2012 Jul;14(7):654-61. doi: 10.1111/j.1463-1326.2012.01602.x. Epub 2012 Apr 22.

PMID:
22443213
5.

Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.

Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.

Pediatr Diabetes. 2013 May;14(3):196-202. doi: 10.1111/pedi.12012. Epub 2013 Jan 4.

PMID:
23289822
6.

Strategies for insulin initiation: insights from the French LIGHT observational study.

Vergès B, Brun JM, Tawil C, Alexandre B, Kerlan V.

Diabetes Metab Res Rev. 2012 Jan;28(1):97-105. doi: 10.1002/dmrr.1288.

PMID:
22218757
7.

An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.

Fujii H, Watanabe Y, Ueki A, Ohno A, Kato M, Kondo K, Takamura H, Takesue M, Nishimura H, Matsuda D, Miyakawa T.

Int J Clin Pract. 2010 Oct;64(11):1512-9. doi: 10.1111/j.1742-1241.2010.02391.x.

PMID:
20678116
8.

A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.

Bowering K, Reed VA, Felicio JS, Landry J, Ji L, Oliveira J.

Diabet Med. 2012 Sep;29(9):e263-72. doi: 10.1111/j.1464-5491.2012.03722.x. Erratum in: Diabet Med. 2012 Nov;29(11):1473. Felicio, J [corrected to Felicio, J S].

PMID:
22672081
9.

Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.

Soewondo P, Kshanti IA, Pramono RB, Langi YA, Dalem-Pemayun TG.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S47-53. doi: 10.1016/S0168-8227(13)70010-X.

PMID:
23647719
10.

Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.

Tripathi S, Chandalia HB, Rao PV, Badgandi M, Patni R, Subbanna PK, Shetty R, Kumar H.

J Indian Med Assoc. 2011 Apr;109(4):275-8.

PMID:
22187803
11.

Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study.

Gómez-Peralta F, Carramiñana-Barrera F, Félix-Redondo FJ, Fraile-Gómez J; Extreme Rescue Study Group.

Int J Clin Pract. 2012 Oct;66(10):959-68. doi: 10.1111/j.1742-1241.2012.03000.x.

PMID:
22994330
12.

Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.

Koivisto V, Cleall S, Pontiroli AE, Giugliano D.

Diabetes Obes Metab. 2011 Dec;13(12):1149-57. doi: 10.1111/j.1463-1326.2011.01484.x.

PMID:
21819517
13.

Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice.

Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini LF, Svendsen AL; SOLVE Study Group.

Endocr Pract. 2013 May-Jun;19(3):462-70. doi: 10.4158/EP12269.OR.

PMID:
23337147
14.

Safety and effectiveness of insulin detemir in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

Soewondo P, Mohamed M, Jain AB, Sy RA, Khoo CM.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S10-6. doi: 10.1016/S0168-8227(13)70004-4.

PMID:
23647712
15.

A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.

Xie L, Wei W, Pan C, Du J, Baser O.

Adv Ther. 2011 Nov;28(11):1000-11. doi: 10.1007/s12325-011-0074-5. Epub 2011 Oct 27.

PMID:
22038703
16.

Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care.

Hajos TR, Pouwer F, de Grooth R, Holleman F, Twisk JW, Diamant M, Snoek FJ.

Diabet Med. 2011 Sep;28(9):1096-102. doi: 10.1111/j.1464-5491.2011.03329.x.

PMID:
21843305
18.
19.

Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir.

O'goshi K, Serup J, Blaaholm B, Thomsen HK, Rossing P, Tarnow L.

Skin Res Technol. 2011 Nov;17(4):411-9. doi: 10.1111/j.1600-0846.2011.00551.x. Epub 2011 Jul 6.

PMID:
21729174
20.

Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.

Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ.

J Med Econ. 2012;15(5):977-86. doi: 10.3111/13696998.2012.692340. Epub 2012 May 23.

PMID:
22563742

Supplemental Content

Support Center